Rheumatoid Arthritis Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Printer-friendly versionPDF version

The Rheumatoid Arthritis Therapeutics Market is Forecast to Show Moderate Growth Until 2018.The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders

GlobalData’s analysis suggests that the global rheumatoid arthritis therapeutics market was worth $10.3
billion in 2010. It is forecast to grow at a compound annual growth rate (CAGR) of 3.8% for the next eight years, to reach $13.8 billion by 2018. The high growth rate during 2005-2010 is primarily attributed to the launch of biologics such as Enbrel (etanercept), Remicade (infliximab), Humira (adalimumab), and
Rituxan (rituximab). The growth was further fuelled by the launch of safer and more efficacious biologics
such as Simponi (golimumab), Acetmra (tocilizumab), Orencia (abatacept) and Cimzia (certolizumab pegol). During the period 2010-2018, the rheumatoid arthritis therapeutics market is expected to have
moderate growth due to the patent expiries of the major biologics and the subsequent launch of biosimilars in the market. The rheumatoid arthritis therapeutics pipeline is strong, with first-in-class and
me-too molecules in the late stage of development, which when launched are expected to off-set generic incursion and drive the market.
 
The rheumatoid arthritis therapeutics market has moderate unmet need. The current therapeutics landscape for rheumatoid arthritis has products that are efficacious but not curative. The efficacy of current product offerings in the rheumatoid arthritis therapeutics market is significant in terms of addressing disease symptoms and improving the lifestyle of the patients. Since rheumatoid arthritis is a
heterogeneous disease patients’ response to the treatment is different; some patients respond to DMARD monotherapy whereas others respond to combination therapies. As a result it remains a major challenge to determine which combination is right for each patient. Most of the available products in the market have a favorable profile, but all these biologics are administered by a parenteral route, which have low compliance rates for drug administration. There are some patients who suffer from adverse effects from the drugs and could benefit from next-generation products.
 
GlobalData’s analysis found that the current competition in the rheumatoid arthritis therapeutics market is strong, and available treatment options have been fairly successful in meeting the market demand. However, they do not have a high safety profile and lack curative properties; this creates market potential for new entrants with products of high efficacy and better safety profiles. Currently, the rheumatoid arthritis therapeutic landscape needs products which can offer a better safety profile alongside diseasemodifying properties, faster onset and longer durations of action. The extent of unmet need in the rheumatoid arthritis therapeutics market is considered to be moderate and can be fulfilled by technologically advanced products that are currently in the rheumatoid arthritis therapeutics pipeline.
 
For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Rheumatoid-Arthritis-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2018&Title=Pharmaceuticals_and_Healthca&ReportType=Industry_Reportd&CompanyID=prpoi
 
GlobalData analysed that the rheumatoid arthritis therapeutics pipeline is strong with 165 molecules in
different stages of development. First-in-class molecules (119) are dominant in the rheumatoid arthritis
therapeutics pipeline. These first-in-class molecules have distinct advantages over the currently marketed products which would bring a change in the disease course and clinical outcome. These molecules are expected to compete strongly with the currently approved products, offering equal or better efficacies and safety profiles leading to increased patient and physician satisfaction. In Phase III there are five first-inclass molecules. Of these, Phase III first-in-class molecules, tofacitinib and fostamatinib look more promising as both are oral formulations which will increase compliance and have low costs compared to the existing products. The launch of these molecules is expected to intensify future competition in the rheumatoid arthritis therapeutics market.
 
GlobalData, the industry analysis specialist, has released its new report, “Rheumatoid Arthritis Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global rheumatoid arthritis therapeutics market. The report identifies the key trends shaping and driving the global rheumatoid arthritis therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global rheumatoid arthritis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and
secondary research and in-house analysis by GlobalData’s team of industry experts.
 
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Rheumatoid-Arthritis-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2018&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthca&CompanyID=prpoi
 
Visit our report store: http://www.globaldata.com/reportstore
 
For more details contact:
pressreleases@globaldata.com
            
North America:                 +1 646 395 5477
Europe:                                +44 207 753 4299
                                                +44 1204 543 533
Asia Pacific:                         +91 40 6616 6782